Trial Profile
A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Ulotaront (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Sunovion Pharmaceuticals
- 09 Nov 2021 Results of pooled analysis evaluating novelty of a safety profile of a drug in a new class (in clinical trials), against that of those already on the market (using pharmacovigilance data) published in the Clinical Drug Investigation
- 05 Oct 2021 Results of an analysis assessing effects of SEP-363856 on negative symptoms in initial double-blind study and 6-month open-label extension study presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
- 05 Oct 2021 Results of pooled analysis assessing the adverse event signals of this first agent in a novel drug class that differentiate it from the available class of atypical antipsychotics, presented at the 34th Annual Congress of the European College of Neuropsychopharmacology.